Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Rating Lowered to Sell at Wall Street Zen

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other analysts have also issued reports on DMRA. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of DMRA stock opened at $20.65 on Friday. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.13 and a beta of 1.43. The stock has a 50 day simple moving average of $27.42 and a 200-day simple moving average of $26.05. Damora Therapeutics, Inc. Common Stock has a 1-year low of $3.64 and a 1-year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. Analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett acquired 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The stock was bought at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the acquisition, the chief executive officer owned 512,500 shares in the company, valued at approximately $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Braidwell LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $42,146,000. Seven Fleet Capital Management LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $7,398,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $303,000. Finally, Arizona State Retirement System acquired a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth $260,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.